Successful management of denosumab discontinuation in a patient with primary pediatric osteoporosis
{{output}}
Treatment of a 13.5-year-old boy with severe primary osteoporosis and multiple vertebral deformities with denosumab (Dmab) 60 mg subcutaneously every 3 months for 30 months, resulted in significant clinical, radiologic and densitometric improvement. During the... ...
